Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Zhang, Mei-Jie  [Clear All Filters]
Journal Article
Fenske TS, Zhang M-J, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, et al. Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality. J Clin Oncol. 2013.
Wagner JE, Ballen KKuhn, Zhang M-J, Allbee-Johnson M, Karanes C, Milano F, Verneris MR, Eapen M, Brunstein CG. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Adv. 2021.
Hamadani M, Zhang M-J, Tang X-Y, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, et al. Graft cryopreservation does not impact overall survival allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide for GVHD prophylaxis. Biol Blood Marrow Transplant. 2020.
Mussetti A, Kanate AS, Wang T, He M, Hamadani M, Sr HFinel, Boumendil A, Glass B, Castagna L, Dominietto A, et al. Haploidentical versus matched unrelated donor transplants using post-transplant cyclophosphamide for lymphomas. Transplant Cell Ther. 2022.
Abid MBilal, Estrada-Merly N, Zhang M-J, Chen K, Allan D, Bredeson C, Sabloff M, Murthy GSubramania, Badar T, Hashmi S, et al. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia. Transplant Cell Ther. 2023.
Saber W, Cutler CS, Nakamura R, Zhang M-J, Atallah E, J Rizzo D, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013.
Cohen S, Bambace N, Ahmad I, Roy J, Tang X, Zhang M-J, Burns LJ, Barabé F, Bernard L, Delisle J-S, et al. Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real-World Evidence. Blood Adv. 2023.
Sharma M, Zhang M-J, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, et al. Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biol Blood Marrow Transplant. 2014.
Solomon SR, St Martin A, Zhang M-J, Ballen K, Bashey A, Battiwalla M, Baxter-Lowe LAnn, Brunstein C, Chhabra S, Perez MAngel Diaz, et al. Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant. Biol Blood Marrow Transplant. 2020.
Magenau JM, Jaglowski SM, Uberti J, Farag SS, Riwes MMansour, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun TM, et al. A Phase 2 Trial of CD24Fc for Prevention of Graft-vs-Host Disease. Blood. 2023.
Orfali N, Zhang M-J, Allbee-Johnson M, Boelens JJan, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, et al. Planned granulocyte-colony stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with Thymoglobulin for myeloid malignancy. Transplant Cell Ther. 2021.
Saber W, Steinert P, Zhang M-J, Chen M, Pope A, Keating A, Wingard JR, Ballen K, Stiff P, Perales M-A, et al. A prospective cohort study comparing long-term outcomes with and without palifermin in patients receiving hematopoietic cell transplantation for hematologic malignancies. Transplant Cell Ther. 2021.
Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, A Al-Homsi S, Aljurf M, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Holter-Chakrabarty JL, Pierson N, Zhang M-J, Zhu X, Akpek G, Aljurf MD, Artz AS, Baron F, Bredeson CN, Dvorak CC, et al. The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplant for Patients with Acute Leukemia. Biol Blood Marrow Transplant. 2015.
Abid MBilal, Merly NEstrada, Zhang M-J, Chen K, Bredeson C, Allan D, Sabloff M, Marks DI, Litzow M, Hourigan C, et al. Younger Matched Unrelated Donors Confer Decreased Relapse Compared to Older Sibling Donors in Older B-cell ALL Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023.